



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/927,914	08/10/2001	Timothy P. Tully	21RE-137270	5180
68850	7590	09/10/2010	EXAMINER	
DON J. PELTO			CHONG, YONG SOO	
Sheppard, Mullin, Richter & Hampton LLP			ART UNIT	PAPER NUMBER
1300 I STREET, NW				1627
11TH FLOOR EAST				
WASHINGTON, DC 20005				
MAIL DATE		DELIVERY MODE		
09/10/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/927,914	TULLY ET AL.	

<b>Examiner</b>	<b>Art Unit</b>	
Yong S. Chong	1627	

**All Participants:**

**Status of Application:** \_\_\_\_\_

(1) Yong S. Chong.

(3) \_\_\_\_\_.

(2) Mr. Don Peltz.

(4) \_\_\_\_\_.

**Date of Interview:** 9 September 2010

**Time:** 3:15 pm

**Type of Interview:**

Telephonic  
 Video Conference  
 Personal (Copy given to:  Applicant  Applicant's representative)

Exhibit Shown or Demonstrated:  Yes  No

If Yes, provide a brief description: \_\_\_\_\_.

**Part I.**

Rejection(s) discussed:

*no*

Claims discussed:

*all pending*

Prior art documents discussed:

*no*

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*See Continuation Sheet*

**Part III.**

It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
 It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

/Yong S. Chong/  
 Primary Examiner, Art Unit 1627

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Upon the conclusion of the pre-appeal conference, several minor issues needs to be addressed before the case is sent to the Board. In particular, Applicant was notified of an issue with claim 8, which recites that all PDE4 inhibitors induce CREB-dependent gene expression. This may be in error as the specification appears to only state that only the augmenting agent, modulators of protein kinases and protein phosphatases mediate CREB-dependent gene expression (last paragraph of page 18). Applicant was asked if it is known in the art that all PDE4 inhibitors induce CREB-dependent gene expression. If this is not the case, Applicant is encouraged to cancel claim 8 in order to simplify all issues to the Board and to expedite prosecution. There are other minor claim amendments that are necessary that was communicated to the Applicant. Examiner will enter the necessary claim amendments after final if the Applicant agrees to make these changes. Examiner awaits an answer. .